296 related articles for article (PubMed ID: 25936872)
1. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.
Bjørn ME; Holmström MO; Hasselbalch HC
Leuk Lymphoma; 2016; 57(1):125-8. PubMed ID: 25936872
[TBL] [Abstract][Full Text] [Related]
2. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV; Winton EF; Natrajan K; Odenike O; Claxton D; Peng W; O'Neill P; Erickson-Viitanen S; Leopold L; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2013 Oct; 6(1):81. PubMed ID: 24283202
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis.
Maccaferri M; Leonardi G; Marasca R; Colaci E; Paolini A; Soci F; Forghieri F; Potenza L; Narni F; Luppi M
Leuk Lymphoma; 2014 Sep; 55(9):2207-8. PubMed ID: 24354678
[No Abstract] [Full Text] [Related]
4. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
5. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
6. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
7. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C; Tam CS; Verstovsek S
Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
Al-Ali HK; Griesshammer M; le Coutre P; Waller CF; Liberati AM; Schafhausen P; Tavares R; Giraldo P; Foltz L; Raanani P; Gupta V; Tannir B; Ronco JP; Ghosh J; Martino B; Vannucchi AM
Haematologica; 2016 Sep; 101(9):1065-73. PubMed ID: 27247324
[TBL] [Abstract][Full Text] [Related]
11. Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?
Breccia M; Molica M; Colafigli G; Alimena G
Expert Rev Hematol; 2015 Aug; 8(4):387-9. PubMed ID: 25915176
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature.
Slot S; Raymakers RAP; Schaap N; Span LFR; Koene HR; Kersting S; Te Boekhorst PAW; Westerman M; Schouten HC; Zweegman S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):624-634. PubMed ID: 31427260
[TBL] [Abstract][Full Text] [Related]
13. Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.
Caocci G; Maccioni A; Murgia F; Perra A; Usai M; Piga M; Mascia R; La Nasa G
Leuk Lymphoma; 2016 May; 57(5):1215-8. PubMed ID: 26308187
[No Abstract] [Full Text] [Related]
14. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
15. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
Saeed I; McLornan D; Harrison CN
Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib for the treatment of primary myelofibrosis.
Swaim SJ
Am J Health Syst Pharm; 2014 Mar; 71(6):453-62. PubMed ID: 24589536
[TBL] [Abstract][Full Text] [Related]
17. Managing patients with myelofibrosis and low platelet counts.
Al-Ali HK; Vannucchi AM
Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
[TBL] [Abstract][Full Text] [Related]
18. Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.
Beauverd Y; Samii K
Int J Hematol; 2014 Nov; 100(5):498-501. PubMed ID: 25034748
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib Enhances Platelet Production in Patients With Thrombocytopenic Myelofibrosis.
Grunwald MR; Spivak JL
J Clin Oncol; 2016 Feb; 34(5):e38-40. PubMed ID: 24958831
[No Abstract] [Full Text] [Related]
20. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
